double-blind gastroscopic evaluation effects etodolac naproxen gastrointestinal mucosa rheumatic patients aim clinical endoscopical study therapeutic efficacy gastric tolerability etodolac new anti-inflammatory non-steroidal drug naproxen study patients rheumatoid arthritis trial initial oesophagogastroduodenoscopy presence gastric mucosal lesions patients treatment etodolac mg b.i.d naproxen mg b.i.d period weeks Endoscopic control treatment period drugs effective clinical symptoms significant difference Gastric mucosal lesions etodolac-treated patients patients naproxen CI Painful dyspepsia patients etodolac patients naproxen therapy study etodolac active naproxen rheumatic symptoms administration results degree gastric damage 